Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial

Affiliations

• ¹ Biogen, Cambridge, MA, USA. tien.dam@biogen.com.
• ² Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.
• ³ Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
• ⁴ Department of Neurology, Technische Universität München, Munich, Germany.
• ⁵ German Center for Neurodegenerative Diseases, Munich, Germany.
• ⁶ Department of Neurology, Hanover Medical School, Hanover, Germany.
• ⁷ National Hospital for Neurology and Neurosurgery, London, UK.
• ⁸ University of California, Parkinson and Other Movement Disorders Center, San Diego, CA, USA.
• ⁹ Edmond J. Safra Program in Parkinson's Disease and the Rossy PSP Centre, Toronto Western Hospital and the University of Toronto, Toronto, Ontario, Canada.
• ¹⁰ Sorbonne Université, Assistance Publique Hôpitaux de Paris, INSERM, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, Hôpital Pitié-Salpêtrière, Paris, France.
• ¹¹ Department of Neurology, National Hospital Organization Higashinagoya National Hospital, Nagoya, Japan.
• ¹² Global R&D Partners, LLC, San Diego, CA, USA.
• ¹³ Biogen, Cambridge, MA, USA.